Rapid Micro Biosystems (RPID) Q2 2026 Earnings Report

The call conveyed clear operational momentum: double-digit revenue growth (11% YoY), record consumable performance (>20% growth), a company milestone (200th system), a sizable increase in service margins (to 49%), and a pathway to improving gross margins through H2 2026 and longer-term targets (50% by end of 2028). At the same time, the company remains unprofitable with a Q2 net loss of $12.9M and adjusted EBITDA loss of $10.3M, product margins are still slightly negative, and liquidity depends on achieving debt milestone funding and potential warrant exercises. Overall, management emphasized improving fundamentals and execution while acknowledging remaining execution and financing risks.

Rapid Micro reaffirmed full‑year 2026 guidance of $37–$41 million in revenue and 30–38 system placements, raised validation guidance to at least 27 completions (with ≥10 in Q3), and expects full‑year gross margin of ~20% (product margin mid‑to‑high single digits; service margin 45–50%). For Q3 they forecast at least $9.5 million of revenue (including ≥7 system placements) and Q3 gross margin ≥20%, with Q4 gross margin targeted in the mid‑to‑high‑20% range (product margin high‑single to low‑double digits; service margin ~50%). They also guided FY OpEx of $51–$53 million, $8 million of non‑cash expense (~$3M D&A, $5M stock comp), $1M CapEx, $1M interest income and $2M interest expense, reported ~ $20M cash at quarter‑end, expect to access a $10M debt tranche later this year (another $10M possible mid‑2027), and are targeting >20% average annual revenue growth and a 50%+ gross margin exit by 2028 with positive cash flow by end‑2028.